<DOC>
	<DOC>NCT03006705</DOC>
	<brief_summary>The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with ONO-4538 in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.</brief_summary>
	<brief_title>Study of Adjuvant ONO-4538 With Resected Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with histologically confirmed adenocarcinoma of the stomach Patients without a remnant cancer (R0) who have undergone gastrectomy Gastric carcinoma according to the stage classification of AJCC/UICC TNM Classification, 7th Edition on the basis of overall postoperative findings Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 Patients who have received nonsurgical treatment (e.g., radiotherapy, chemotherapy, hormone therapy) for gastric cancer Multiple primary cancers A current or past history of severe hypersensitivity to any other antibody products Any concurrent autoimmune disease or past history of chronic or recurrent autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ONO-4538,BMS-936558,Nivolumab,gastric,adjuvant,S-1,CapeOX</keyword>
</DOC>